Pillars of growth
Heavy bet for R&D&i
as a future
growth engine
Heavy bet on R&D&i
as a future
growth engine
Enoxaparin biosimilar
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Bemiparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
Contract manufacturing
High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
+32%
2016 net profit
+9%
2016 Bemiparin sales in Spain
55 countries
International presence with 22 international partners
4 plants
for manufacturing own and third-party products in Spain
17,5 Mn€
of investment in R&D en 2016 Commitment to innovation
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
07/14/2017 - 16:46
07/14/2017 - 16:45
